Philip D. Hall

903 total citations
32 papers, 712 citations indexed

About

Philip D. Hall is a scholar working on Immunology, Biotechnology and Molecular Biology. According to data from OpenAlex, Philip D. Hall has authored 32 papers receiving a total of 712 indexed citations (citations by other indexed papers that have themselves been cited), including 21 papers in Immunology, 13 papers in Biotechnology and 6 papers in Molecular Biology. Recurrent topics in Philip D. Hall's work include Toxin Mechanisms and Immunotoxins (18 papers), Transgenic Plants and Applications (13 papers) and Neuroblastoma Research and Treatments (4 papers). Philip D. Hall is often cited by papers focused on Toxin Mechanisms and Immunotoxins (18 papers), Transgenic Plants and Applications (13 papers) and Neuroblastoma Research and Treatments (4 papers). Philip D. Hall collaborates with scholars based in United States, Canada and Australia. Philip D. Hall's co-authors include Arthur E. Frankel, Robert J. Kreitman, Mark C. Willingham, Edward P. Tagge, Bayard L. Powell, L. Douglas Case, Arthur E. Frankel, Tie Fu Liu, John B. Bossaer and Elizabeth Garrett‐Mayer and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Clinical Cancer Research.

In The Last Decade

Philip D. Hall

32 papers receiving 702 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Philip D. Hall United States 17 384 258 196 193 102 32 712
Oettgen Hf United States 14 253 0.7× 191 0.7× 49 0.3× 199 1.0× 49 0.5× 30 719
R. Schnell Germany 12 215 0.6× 90 0.3× 119 0.6× 153 0.8× 45 0.4× 28 469
R. N. Taub United States 15 218 0.6× 235 0.9× 22 0.1× 206 1.1× 168 1.6× 35 819
John Leslie Collins United States 15 491 1.3× 262 1.0× 35 0.2× 143 0.7× 29 0.3× 48 964
Moshe Glaser United States 19 632 1.6× 232 0.9× 55 0.3× 267 1.4× 52 0.5× 40 1.0k
J.M.C. Wessels Netherlands 12 145 0.4× 202 0.8× 64 0.3× 76 0.4× 30 0.3× 27 497
O Hallé-Pannenko France 16 511 1.3× 135 0.5× 41 0.2× 172 0.9× 41 0.4× 67 772
A M Kaplan United States 17 446 1.2× 169 0.7× 31 0.2× 150 0.8× 124 1.2× 43 839
Ariel Ramírez-Labrada Spain 15 296 0.8× 325 1.3× 25 0.1× 293 1.5× 96 0.9× 28 740
Ulrich Mack Germany 16 127 0.3× 251 1.0× 16 0.1× 154 0.8× 42 0.4× 26 860

Countries citing papers authored by Philip D. Hall

Since Specialization
Citations

This map shows the geographic impact of Philip D. Hall's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Philip D. Hall with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Philip D. Hall more than expected).

Fields of papers citing papers by Philip D. Hall

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Philip D. Hall. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Philip D. Hall. The network helps show where Philip D. Hall may publish in the future.

Co-authorship network of co-authors of Philip D. Hall

This figure shows the co-authorship network connecting the top 25 collaborators of Philip D. Hall. A scholar is included among the top collaborators of Philip D. Hall based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Philip D. Hall. Philip D. Hall is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Smith, Marie, et al.. (2013). Report of the 2012-2013 Standing Committee on Advocacy: Advocacy Tools and Resources: A Framework for Increasing Member Engagement. American Journal of Pharmaceutical Education. 77(10). S17–S17. 3 indexed citations
2.
Bossaer, John B., Philip D. Hall, & Elizabeth Garrett‐Mayer. (2010). Incidence of vancomycin-resistant enterococci (VRE) infection in high-risk febrile neutropenic patients colonized with VRE. Supportive Care in Cancer. 19(2). 231–237. 45 indexed citations
3.
McDonnell, Anne, et al.. (2006). Single‐Dose Rasburicase 6 mg in the Management of Tumor Lysis Syndrome in Adults. Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy. 26(6). 806–812. 60 indexed citations
4.
Hall, Philip D., Debajyoti Sinha, & Arthur E. Frankel. (2006). Fresh frozen plasma and platelet concentrates may increase plasma anti-diphtheria toxin IgG concentrations: implications for diphtheria fusion protein therapy. Cancer Immunology Immunotherapy. 55(8). 928–932. 2 indexed citations
5.
6.
Liu, Tie Fu, et al.. (2004). Safety evaluation of DT388IL3, a diphtheria toxin/interleukin 3 fusion protein, in the cynomolgus monkey. Cancer Immunology Immunotherapy. 54(8). 799–806. 24 indexed citations
7.
Black, J, Philip D. Hall, Mark C. Willingham, et al.. (2003). Expression and purification of the recombinant diphtheria fusion toxin DT388IL3 for phase I clinical trials. Protein Expression and Purification. 33(1). 123–133. 35 indexed citations
8.
9.
Frankel, Arthur E., Jason G. Ramage, Stephen J. Delatte, et al.. (1999). High-Level Expression and Purification of the Recombinant Diphtheria Fusion Toxin DTGM for PHASE I Clinical Trials. Protein Expression and Purification. 16(1). 190–201. 28 indexed citations
10.
Kim, Caryn N., Kapil N. Bhalla, Robert J. Kreitman, et al.. (1999). Diphtheria toxin fused to granulocyte-macrophage colony-stimulating factor and Ara-C exert synergistic toxicity against human AML HL-60 cells. Leukemia Research. 23(6). 527–538. 22 indexed citations
11.
Hotchkiss, Charlotte E., Philip D. Hall, J. Mark Cline, et al.. (1999). Toxicology and Pharmacokinetics of DTGM, a Fusion Toxin Consisting of a Truncated Diphtheria Toxin (DT388) Linked to Human Granulocyte-Macrophage Colony-Stimulating Factor, in Cynomolgus Monkeys. Toxicology and Applied Pharmacology. 158(2). 152–160. 20 indexed citations
12.
Frankel, Arthur E., Michelle M. Lilly, Robert J. Kreitman, et al.. (1998). Diphtheria toxin fused to granulocyte-macrophage colony-stimulating factor is toxic to blasts from patients with juvenile myelomonocytic leukemia and chronic myelomonocytic leukemia.. Blood. 92(11). 4279–86. 30 indexed citations
13.
Hall, Philip D., R. J. Kreitman, Mark C. Willingham, & Arthur E. Frankel. (1998). Toxicology and Pharmacokinetics of DT388-GM-CSF, a Fusion Toxin Consisting of a Truncated Diphtheria Toxin (DT388) Linked to Human Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) in C57BL/6 Mice. Toxicology and Applied Pharmacology. 150(1). 91–97. 11 indexed citations
14.
Frankel, Arthur E., et al.. (1998). Cell-Specific Modulation of Drug Resistance in Acute Myeloid Leukemic Blasts by Diphtheria Fusion Toxin, DT388-GMCSF. Bioconjugate Chemistry. 9(4). 490–496. 26 indexed citations
15.
Tagge, Edward P., et al.. (1997). Synthesis of Green Fluorescent Protein−Ricin and Monitoring of Its Intracellular Trafficking. Bioconjugate Chemistry. 8(5). 743–750. 8 indexed citations
16.
Hall, Philip D., et al.. (1995). The influence of serum tumor necrosis factor-alpha and interleukin-6 concentrations on nonhematologic toxicity and hematologic recovery in patients with acute myelogenous leukemia.. PubMed. 23(12). 1256–60. 32 indexed citations
17.
Hall, Philip D.. (1993). Immunomodulation With Intravenous Immunoglobulin. Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy. 13(6). 564–573. 19 indexed citations
18.
Hall, Philip D. & Jim M. Koeller. (1990). Head and Neck Cancer: Detection and Therapeutics. American Pharmacy. 30(4). 28–32. 4 indexed citations
19.
Hall, Philip D., et al.. (1989). The Effect of Everyday Exercise on Steady State Digoxin Concentrations. The Journal of Clinical Pharmacology. 29(12). 1083–1088. 4 indexed citations
20.
Gourlay, G. K., et al.. (1987). Halothane hepatitis in an animal model: time course of hepatic damage.. PubMed. 68(5). 613–24. 8 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Oettgen Hf Breakdown of academic impact, for papers by R. Schnell Breakdown of academic impact, for papers by R. N. Taub Breakdown of academic impact, for papers by John Leslie Collins Breakdown of academic impact, for papers by Moshe Glaser Breakdown of academic impact, for papers by J.M.C. Wessels Breakdown of academic impact, for papers by O Hallé-Pannenko Breakdown of academic impact, for papers by A M Kaplan Breakdown of academic impact, for papers by Ariel Ramírez-Labrada Breakdown of academic impact, for papers by Ulrich Mack
Rankless by CCL
2026